Fact CheckerSign in

NCT06013722Active, not recruiting

Strategy for Unstable Coronary Plaque in Patients Presenting to Emergency Department for Chest Pain Suspected of Coronary Artery Disease

Strategy for Unstable Coronary Plaque in Patients Presenting to the Emergency Department for Chest Pain Suspected of Coronary Artery Disease. A Trial in Primary Prevention and Cardiovascular Risks Evaluation

Source: ClinicalTrials.gov · Last updated 7 Jul 2026

Brief summary (registry, in English)

Primary prevention of coronary disease and especially its major complication, inaugural myocardial infarction, is based on any prodromal symptoms identification and on risk profile establishment. About 50% of myocardial infarctions are caused by an unstable non-stenosing plaque, asymptomatic before the event since without significant reduction in coronary flow, particularly during a stress test or during stress imaging. Study purpose is to set up, in medical emergency department, check-up unit and cardiology department, a primary prevention strategy articulated around a routine examination: calcium scoring. The latter makes it possible to categorize patients according to their risk of generating atheromatous plaques and to classify them into several risk levels (groups) according to their score: low (\<40th percentile), intermediate (between the 40th percentile and the 65th percentile: group III) or high risk (\>65th percentile, group IV). 18F-Na PET scan can mark unstable coronary plaques. For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
22 (actual)
First submitted
29 Jul 2023
Start date
18 Mar 2024
Primary completion date
24 Jul 2025
Lead sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
NCT number
NCT06013722

What you commit to

  • Study type: Interventional
  • Participants enrolled: 22
  • From 18 Mar 2024 to the primary completion date, 24 Jul 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patient with contraindications or intolerances to HMG-CoA reductase inhibitors (statins) and/or Ezetimibe

Other illness

  • Patient with cognitive disorders
  • Patient with liver failure
  • Patient with myopathy or with a history of (rhabdo)myolysis
  • Marked arrhythmia and in particular supraventricular or ventricular hyperexcitability, or chronic or paroxysmal atrial fibrillation not controlled by antiarrhythmic treatment
  • Patients with a history of sternotomy or valve replacement or metallic intracardiac probes, generators of scanner artefacts
  • For patients in groups III and IV:
    • renal insufficiency with glomerular filtration rate estimated by the MDRD and/or CKD-EPI formula less than or equal to 55 ml/min/1.73 m2,
    • known intolerance to radiological contrast products, or in whom an injected CT scan has already been performed in the 6 months preceding inclusion

Lab values

  • Calcium score corresponding to the percentiles of groups I and II

Other

  • Pregnant woman
  • Claustrophobic patient, or refusing radiological examinations
  • Patient refusing cardiological follow-up and/or treatment of his risk factors or refusing to participate in the study
  • Person participating in another biomedical research
  • Person under judicial protection (guardianship, curatorship...)
  • Person deprived of liberty by a judicial or administrative decision.

Who the study is looking for

  • Patient with no coronary history presenting to the emergency room, to the assessment unit or having consulted in the cardiology department for suspicious chest pain that does not allow an acute coronary syndrome or angina to be excluded and:
    • in whom the diagnosis of acute coronary syndrome has been ruled out on the basis of clinical, electrocardiographic, biological monitoring, or even by imaging (including coronary angiography), in accordance with recommendations and good practices
    • in whom effort myocardial ischemia is rendered unlikely on the basis of a clinical and paraclinical evaluation (either ergometric or by functional imaging: scintigraphy, echography or stress MRI)
    • wishing diagnostic care and primary prevention of coronary disease.
  • Age above or equal to 18 and strictly below 80 years old
  • Having given informed consent

Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre Hospitalier Princesse Grace
Coordinator of this site? Confirm its status
MonacoMonacoUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.